A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria for Tumor Collection: * Participants must have an established diagnosis of multiple myeloma * Participant must have multiple myeloma and have relapsed following or are refractory to proteasome inhibitors, IMiDs and anti-CD38 mAb therapy * Participants must have at least 3 prior lines of therapy * Participants must be ≥18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Participants must have \> 20% plasma cells in the bone marrow core or aspirate differential \<30 days prior to enrollment. * ANC \> 1K/uL; Platelets \> 50 K/uL without transfusional support * Participants must have adequate organ function as defined below: * Total bilirubin ≤1.5 x institutional upper limit of normal * AST ≤ 3 x institutional upper limit of normal * ALT ≤ 3 x institutional upper limit of normal * Creatinine clearance ≥ 40 mL/min for participants with creatinine levels above institutional normal * The effects of DC/MM fusion vaccine on the devel…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source